The Valley Desk

ArticleLiver cancerPublished

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Liver cancer
Published
Subject terms
Neratinib; Fibrolamellar Carcinoma; Pan-her Kinase Inhibition; Summit Phase 2 Basket Study
PubMed ID
40144471
PubMed Central ID
PMC11936434
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal